Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Non-Current Assets (2016 - 2025)

Abeona Therapeutics has reported Other Non-Current Assets over the past 15 years, most recently at $781000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $781000.0 for Q4 2025, up 131.07% from a year ago — trailing twelve months through Dec 2025 was $781000.0 (up 131.07% YoY), and the annual figure for FY2025 was $781000.0, up 131.07%.
  • Other Non-Current Assets for Q4 2025 was $781000.0 at Abeona Therapeutics, up from $541000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for ABEO hit a ceiling of $5.9 million in Q4 2021 and a floor of $43000.0 in Q4 2022.
  • Median Other Non-Current Assets over the past 5 years was $338000.0 (2023), compared with a mean of $1.5 million.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 99.27% in 2022 and later skyrocketed 686.05% in 2023.
  • Abeona Therapeutics' Other Non-Current Assets stood at $5.9 million in 2021, then tumbled by 99.27% to $43000.0 in 2022, then skyrocketed by 686.05% to $338000.0 in 2023, then changed by 0.0% to $338000.0 in 2024, then skyrocketed by 131.07% to $781000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $781000.0 (Q4 2025), $541000.0 (Q3 2025), and $338000.0 (Q2 2025) per Business Quant data.